EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Beyond lipid lowering: targeting lncRNAs as a novel therapeutic strategy for vascular wall defense in atherosclerosis

Yu Chen, Yuxin Shang, Shanpeng Liu, Yuqing Pan, Chenxia Wu, Chenchen Meng, Tiantian Zheng, Wei Mao, Tingting Chen

Pharmacological Research · 2026

DOI: 10.1016/j.phrs.2026.108342 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmacological Research, 2026. Verfasst von Yu Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Key Laboratory of Integrative Chinese and Western Medicine for Diagnosis and Treatment of Circulatory Diseases, Zhejiang Hospital (Affiliate…. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Atherosclerosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 214 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Zhejiang Province Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atherosclerosis remains the primary pathological foundation for severe cardiovascular events. Although guideline-directed medical therapy-particularly statins, cholesterol absorption inhibitors, and PCSK9 inhibitors-effectively reduces circulating low-density lipoprotein cholesterol (LDL-C), the risk of major adverse cardiovascular events driven by vulnerable plaque rupture persists. Conventional therapies alleviate systemic lipid burdens but fail to adequately reverse localized immune dysregulation and structural damage in situ within the vascular wall. Consequently, cardiovascular precision medicine is shifting towards actively rebuilding the vascular wall defense system. Leveraging their high tissue specificity and epigenetic regulatory capabilities, long non-coding RNAs (lncRNAs) serve as critical hubs for vascular homeostasis, representing novel therapeutic targets for reconstructing this defense network. This review summarizes how aberrant lncRNAs disrupt endothelial barriers, drive vascular smooth muscle cell dedifferentiation, and induce macrophage dyshomeostasis, while emphasizing the necessity of rigorously validating competing endogenous RNA mechanisms. To actualize in situ intervention, we highlight advances in nucleic acid therapeutics (antisense oligonucleotides and small interfering RNAs) and sophisticated nanodelivery systems-including biomimetic coatings and active targeting-that overcome extrahepatic delivery barriers for deep-plaque penetration. Finally, we address critical translational hurdles (interspecies conservation, off-target toxicity), evaluate circulating lncRNA biomarkers, and propose integrating lncRNA interventions with existing pharmacotherapies. Empowered by artificial intelligence for rational target discovery and theranostic nanoplatforms, lncRNA-directed therapies promise to mitigate persistent plaque vulnerability and advance cardiovascular precision medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Long NoncodingAtherosclerosisHumansAnimalsOligonucleotides, AntisensePlaque, Atherosclerotic

Stichwörter der Autor:innen

AtherosclerosisLong non-coding RNANucleic acid therapeuticsTargeted deliveryTheranosticsVascular wall defense

Substanzen

RNA, Long NoncodingOligonucleotides, Antisense

Autor:innen und Institutionen

  • Zhejiang Key Laboratory of Integrative Chinese and Western Medicine for Diagnosis and Treatment of Circulatory Diseases, Zhejiang Hospital (Affiliated Zhejiang Hospital, Zhejiang University School of Medicine), Hangzhou…

Förderung

  • Zhejiang Province Natural Science Foundation

Zitieren

APA

Chen, Y., Shang, Y., Liu, S., Pan, Y., Wu, C., Meng, C., Zheng, T., Mao, W., & Chen, T. (2026). Beyond lipid lowering: targeting lncRNAs as a novel therapeutic strategy for vascular wall defense in atherosclerosis. Pharmacological Research. https://doi.org/10.1016/j.phrs.2026.108342

Vancouver

Chen Y, Shang Y, Liu S, Pan Y, Wu C, Meng C, et al. Beyond lipid lowering: targeting lncRNAs as a novel therapeutic strategy for vascular wall defense in atherosclerosis. Pharmacological Research. 2026. doi:10.1016/j.phrs.2026.108342

BibTeX
@article{Chen2026,
  author = {Chen, Yu and Shang, Yuxin and Liu, Shanpeng and Pan, Yuqing and Wu, Chenxia and Meng, Chenchen and Zheng, Tiantian and Mao, Wei and Chen, Tingting},
  title = {Beyond lipid lowering: targeting lncRNAs as a novel therapeutic strategy for vascular wall defense in atherosclerosis},
  journal = {Pharmacological Research},
  year = {2026},
  doi = {10.1016/j.phrs.2026.108342}
}
Kostenlos starten →